Physician profile
Osman Ali
NPI 1639606429
$32,544.09
in general payments reported to CMS, 2019-2025
26 companies · $8,704 in 2025
The $8,704 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.02 · 2021: $229 · 2022: $623 · 2023: $2,335 · 2024: $21K · 2025: $8,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $20K · Travel and Lodging: $5,312 · Food and Beverage: $4,958 · Consulting Fee: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $20,000.00 |
| Travel and Lodging | $5,312.17 |
| Food and Beverage | $4,958.02 |
| Consulting Fee | $1,400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $23,134.82 | 2023-2025 | Axios, Exalt Model D, Accolade Sr |
| Conmed Corporation | $4,919.56 | 2025 | Conmed Biliary, Conmed Hemostasis |
| Olympus Corporation of The Americas | $1,731.91 | 2023 | Visiglide, Disposable Distal Attachment, Single Use Electrosurgical Knife Kd-655 |
| Medtronic, INC. | $743.88 | 2021-2025 | Gi Genius, Endoflip |
| Abbvie INC. | $607.81 | 2021-2025 | |
| Janssen Biotech, INC. | $175.68 | 2025 | Tremfya |
| Bioventus LLC | $146.99 | 2023 | Stimrouter Implantable Kit |
| Gilead Sciences, INC. | $139.91 | 2022-2025 | |
| Apollo Endosurgery US INC | $110.90 | 2023 | Overstitch Endoscopic Suturing System |
| Phathom Pharmaceuticals, INC. | $110.44 | 2024-2025 | Voquezna |
| Micro-Tech Endoscopy USA, INC. | $101.73 | 2025 | Eyemax |
| Takeda Pharmaceuticals U.S.A., INC. | $95.54 | 2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.58 | 2024-2025 | Xifaxan |
| Lilly USA, LLC | $90.67 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $86.24 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $43.15 | 2020-2025 | Uplizna |
| Mallinckrodt Hospital Products INC. | $26.65 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $22.99 | 2025 | Dupixent |
| Novo Nordisk INC | $21.82 | 2025 | Wegovy |
| Ambu INC. | $21.62 | 2023 | |
| Aimmune Therapeutics, INC. | $20.64 | 2025 | Zenpep |
| Genzyme Corporation | $20.52 | 2025 | |
| Daiichi Sankyo INC. | $20.42 | 2025 | Injectafer |
| Celltrion USA INC. | $20.08 | 2025 | Vegzelma |
| Siemens Medical Solutions USA, INC. | $20.00 | 2021 | |
| Nestle Healthcare Nutrition INC. | $18.54 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Osman Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.